NYSEAMERICAN:SYNSynthetic Biologics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Synthetic Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.31 -0.01 (-3.16 %) (As of 04/7/2020 03:33 PM ET) Add Compare Share Today's Range$0.29Now: $0.31▼$0.3350-Day Range N/A52-Week Range$0.25Now: $0.31▼$0.68Volume229,558 shsAverage Volume286,239 shsMarket Capitalization$5.19 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Synthetic Biologics, Inc., a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases, and monoclonal antibody therapies that prevents and treats pertussis. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Synthetic Biologics. Previous Next 2.7 Community Rank Outperform VotesSynthetic Biologics has received 467 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSynthetic Biologics has received 386 “underperform” votes. (Add your “underperform” vote.)Community SentimentSynthetic Biologics has received 54.75% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote “Outperform” if you believe SYN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSynthetic Biologics does not currently pay a dividend.Dividend GrowthSynthetic Biologics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Synthetic Biologics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:SYN Previous Symbol CUSIPN/A CIK894158 Webhttp://www.syntheticbiologics.com/ Phone+1-734-3327800Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees13 Outstanding Shares16,957,000Market Cap$5.19 million Next Earnings Date5/13/2020 (Estimated) OptionableNot Optionable Receive SYN News and Ratings via Email Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter. AMEX:SYN Rates by TradingView Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions When is Synthetic Biologics' next earnings date? Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Synthetic Biologics. How were Synthetic Biologics' earnings last quarter? Synthetic Biologics Inc (NYSEAMERICAN:SYN) issued its quarterly earnings data on Thursday, February, 20th. The company reported ($0.19) earnings per share for the quarter. View Synthetic Biologics' earnings history. When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work? Shares of Synthetic Biologics reverse split on the morning of Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split. Has Synthetic Biologics been receiving favorable news coverage? Media stories about SYN stock have trended very negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Synthetic Biologics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutSynthetic Biologics. Who are some of Synthetic Biologics' key competitors? Some companies that are related to Synthetic Biologics include Fusion Antibodies (FAB), Pharmaust (PAA), Ceapro (CZO), Acrux (ACR), BTC Health (BTC), Exopharm (EX1), Adalta (1AD), Regeneus (RGS), Navidea Biopharmaceuticals (NAVB), Suda Pharmaceuticals (SUD), ImmuPharma (IMM), Can-Fite Biopharma (CANF), Kane Biotech (KNE), NovaBay Pharmaceuticals (NBY) and Immuron (IMC). What other stocks do shareholders of Synthetic Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synthetic Biologics investors own include Synergy Pharmaceuticals (SGYP), Tonix Pharmaceuticals (TNXP), Agenus (AGEN), NovaBay Pharmaceuticals (NBY), Rigel Pharmaceuticals (RIGL), Energy Transfer LP Unit (ET), Actinium Pharmaceuticals (ATNM), Protalix Biotherapeutics (PLX), ACADIA Pharmaceuticals (ACAD) and Rexahn Pharmaceuticals (REXN). Who are Synthetic Biologics' key executives? Synthetic Biologics' management team includes the following people: Mr. Steven A. Shallcross CPA, CEO, CFO, Treasurer, Corp. Sec. & Director (Age 58)Vincent I. Perrone, Director of Corp. CommunicationDr. Vince Wacher, Head of Product and Corp. Devel.Dr. Michael Kaleko, Sr. VP of R&DDr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing What is Synthetic Biologics' stock symbol? Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN." How do I buy shares of Synthetic Biologics? Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Synthetic Biologics' stock price today? One share of SYN stock can currently be purchased for approximately $0.31. How big of a company is Synthetic Biologics? Synthetic Biologics has a market capitalization of $5.19 million. Synthetic Biologics employs 13 workers across the globe. View additional information about Synthetic Biologics. What is Synthetic Biologics' official website? The official website for Synthetic Biologics is http://www.syntheticbiologics.com/. How can I contact Synthetic Biologics? Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800. This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: What is a stock portfolio tracker?
